Table 3.
Odds ratios (ORs) and 95% confidence intervals (CIs) for the association of a 1 log10 increase in baseline HPV16 or HPV18 DNA load with type-specific positivity at month 6 visit, stratified by coinfection with other types, current smoking status, or cervical cytology at enrollment
| Baseline HPV16 DNA load in women | Baseline HPV18 DNA load in women | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| remaining positive |
becoming negative |
remaining positive |
becoming negative |
|||||||
| Stratum | No. | Mean (SD) | No. | Mean (SD) | OR(95% CI)a | No. | Mean (SD) | No. | Mean (SD) | OR (95% CI)a |
| Coinfection | ||||||||||
| No | 86 | 2.89 (1.39) | 99 | 3.04 (1.29) | 1.04 (0.79–1.36) | 26 | 4.46 (1.31) | 34 | 4.19 (1.97) | 1.08 (0.76–1.53) |
| Yes | 193 | 3.05 (1.12) | 257 | 2.44 (1.42) | 1.53 (1.29–1.82) | 76 | 3.94 (1.54) | 109 | 3.37 (1.69) | 1.35 (1.09–1.68) |
| Current smoking | ||||||||||
| No | 150 | 2.87 (1.24) | 203 | 2.58 (1.38) | 1.31 (1.09–1.59) | 63 | 3.98 (1.43) | 87 | 3.34 (1.71) | 1.26 (1.00–1.59) |
| Yes | 129 | 3.16 (1.16) | 153 | 2.65 (1.46) | 1.45 (1.17–1.79) | 39 | 4.22 (1.60) | 56 | 3.91 (1.87) | 1.38 (0.99–1.91) |
| Cervical cytology b | ||||||||||
| Within normal limits | 54 | 2.08 (1.20) | 64 | 1.38 (1.30) | 1.52 (1.11–2.07) | 20 | 3.23 (1.45) | 30 | 2.24 (1.79) | 1.75 (1.11–2.77) |
| ASC-US | 79 | 2.98 (1.16) | 101 | 2.56 (1.23) | 1.35 (1.04–1.75) | 27 | 4.14 (1.18) | 40 | 3.56 (1.74) | 1.30 (0.91–1.86) |
| LSIL | 103 | 3.28 (1.01) | 105 | 2.90 (1.40) | 1.32 (1.04–1.69) | 51 | 4.27 (1.54) | 50 | 4.11 (1.59) | 1.11 (0.87–1.43) |
| HSIL | 42 | 3.60 (1.02) | 82 | 3.27 (1.09) | 1.37 (0.94–1.99) | 4 | 5.35 (1.54) | 23 | 4.12 (1.42) | |
NOTE. Associating per 1 log10 unit increase in baseline HPV16 or HPV18 DNA load with type-specific positivity at month 6, adjusted for all variables listed in the table except for the stratifier
Excluded were 5 HPV16-positive women whose enrollment samples were inadequate for cytologic diagnosis. Because of the limited number of women with HSIL who remained HPV18-positive at month 6, women with HSIL were grouped with those with LSIL for analysis of risk association.